December MIMS Update

Guest Author 12/12/2025

Some of the recent changes to the medicines landscape, with new indications and contraindications New Indications Durvalumab (Imfinzi) in combination with gemcitabine and cisplatin is now also indicated as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with muscle invasive bladder cancer. Normal immunoglobulin (human) and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

December MIMS Update

Previous New CPD standards released

Next ‘You’re going to give me everything’

MENU

ajp.com.au

Previous New CPD standards released

Next ‘You’re going to give me everything’

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.